← feed

Is NCT03135951 results overdue?

Yes — results are overdue. Primary completion was 2018-02-19; the FDAAA-801 reporting deadline (2019-02-19) passed 2725 days ago and no results are posted on ClinicalTrials.gov.

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

NCT IDNCT03135951 ↗
SponsorSpectrum Pharmaceuticals, Inc (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-02-19 (ACTUAL)
Reporting deadline2019-02-19 (completion + 365d)
Days overdue2725
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 048d9e362380cfa4… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03135951. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →